Physician profile
Niranjan Siva
NPI 1154330157
$9,622.77
in general payments reported to CMS, 2019-2025
59 companies · $453 in 2025
The $453 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,563 · 2020: $1,781 · 2021: $1,040 · 2022: $1,729 · 2023: $2,705 · 2024: $351 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636 · Education: $723 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,636.35 |
| Education | $723.28 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,217.75 | 2021-2025 | Ubrelvy, Botox, Duopa |
| Allergan, INC. | $983.22 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $926.97 | 2019-2024 | Ultomiris, Soliris |
| Supernus Pharmaceuticals, INC. | $640.02 | 2019-2022 | |
| Pfizer INC. | $539.14 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $382.36 | 2022 | |
| Biogen, INC. | $365.50 | 2019-2023 | Tysabri, Vumerity |
| Avanir Pharmaceuticals, INC. | $341.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $322.24 | 2019-2023 | |
| Amgen INC. | $281.98 | 2019-2022 | |
| Sk Life Science, INC. | $254.43 | 2020-2023 | |
| Acadia Pharmaceuticals INC | $233.15 | 2019-2023 | Nuplazid |
| Celgene Corporation | $221.19 | 2021-2023 | Zeposia |
| Sunovion Pharmaceuticals INC. | $208.38 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $206.42 | 2019-2023 | Austedo, Austedo Xr |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niranjan Siva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.